Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 9/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 7/20 | 0.38 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.35 |
| ▸ | HTR3B | O95264 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.35 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25942088 | 0.78 | TGFBR1 (0.43) | TGFBR1DYRK1AACVR1BIRAK4 | |
| SCHEMBL25336872 | 0.77 | TGFBR1 (0.53) | TGFBR1ACVR1BIRAK4 | |
| SCHEMBL25942360 | 0.76 | TGFBR1 (0.46) | TGFBR1DYRK1AIRAK4 | |
| SCHEMBL25334386 | 0.76 | TGFBR1 (0.55) | TGFBR1ACVR1BSCN5AIRAK4 | |
| SCHEMBL25942173 | 0.75 | TGFBR1 (0.60) | TGFBR1ACVR1BIRAK4 | |
| SCHEMBL25942893 | 0.75 | TGFBR1 (0.43) | TGFBR1DYRK1AACVR1BSCN5AIRAK4 | |
| SCHEMBL25942612 | 0.74 | TGFBR1 (0.52) | TGFBR1DYRK1ASCN5AIRAK4HTR3E | |
| SCHEMBL2750457 | 0.73 | TGFBR1 (0.51) | TGFBR1DYRK1ASCN5A | |
| SCHEMBL3359544 | 0.71 | TGFBR1 (0.53) | TGFBR1ACVR1BIRAK4 | |
| SCHEMBL25942083 | 0.70 | TGFBR1 (0.55) | TGFBR1DYRK1AACVR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303562-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230303562-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| EP-4219453-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2023-08-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303562-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | CYP51A1, CYP4F11, WEE1 | TGFBR1 1681/4885DYRK1A 4733/4885ACVR1B 884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.